1. Home
  2. GNS vs ACET Comparison

GNS vs ACET Comparison

Compare GNS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genius Group Limited

GNS

Genius Group Limited

SELL

Current Price

$0.49

Market Cap

32.1M

Sector

Real Estate

ML Signal

SELL

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$2.14

Market Cap

28.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNS
ACET
Founded
2002
1947
Country
Singapore
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.1M
28.0M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
GNS
ACET
Price
$0.49
$2.14
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $29.00
AVG Volume (30 Days)
★ 2.5M
284.0K
Earning Date
09-28-2026
11-05-2026
Dividend Yield
★ 197.24%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$127.02
N/A
Revenue Next Year
$36.19
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.09
$0.46
52 Week High
$0.83
$9.97

Technical Indicators

Market Signals
Indicator
GNS
ACET
Relative Strength Index (RSI) 90.23 13.48
Support Level $0.36 N/A
Resistance Level N/A $9.51
Average True Range (ATR) 0.03 0.26
MACD 0.02 0.06
Stochastic Oscillator 59.66 0.84

Price Performance

Historical Comparison
GNS
ACET

About GNS Genius Group Limited

Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: